- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01700751
Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation
A Pilot Study of Brentuximab Vedotin in the Prevention of Graft-Versus-Host Disease (GVHD) After Unrelated Allogeneic Stem Cell Transplantation
Studienübersicht
Status
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Missouri
-
Saint Louis, Missouri, Vereinigte Staaten, 63110
- Washington University School of Medicine
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
Patient must be scheduled to undergo stem cell transplantation for one of the following diagnoses:
- acute myeloid leukemia (AML) in CR1 (first complete remission, CR or CRi) or CR2 (second complete remission, CR or CRi),
- acute lymphoblastic leukemia (ALL) in CR1 or CR2 (CR or CRi)
- myelodysplastic syndrome (MDS) without progression to AML.
- Chronic myelogenous leukemia (CML)
- Non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD)
- Chronic lymphocytic leukemia (CLL)
- Multiple myeloma (MM)
- Patients must be the recipient of unrelated donor peripheral blood stem cell products. Mismatches at both antigen and allele level will be eligible. Match must be 6 or 7 out of 8 loci (HLA A, B, C, and DRB1).
- Patient must receive any one of the following conditioning regimens: total body radiation (single or fractionated dose)/cyclophosphamide, busulfan/ cyclophosphamide, or fludarabine/busulfan/lymphocyte immune globulin (ATGAM/thymo).
- Patient must be ≥ 18 years and ≤ 70 years of age.
- Patient must have an ECOG performance status ≤ 2 or Karnofsky performance scale ≥ 60%
- Patient must have CD34+ stem cells ≥ 2x106/kg (actual body weight of the recipient) available for transplantation.
Patient must have appropriate organ function as defined below (this criterion should be met on screening and on the day of the first dose of brentuximab vedotin (as assessed prior to dosing)):
- Total bilirubin ≤ 2.0 x IULN
- AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN
- Serum creatinine ≤ 2.0 x IULN
- Estimated Creatinine Clearance > 30 ml/min
- Cardiac ejection fraction > 40%
- DLCO/VA > 40%
- Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
- Patient must be able to understand and willing to sign an IRB approved written informed consent document.
Exclusion Criteria:
- Patient must not have had prior exposure to brentuximab vedotin.
- Patient must not have a history of other malignancy that has not been in remission for at least 3 years, with the exception of basal non-melanoma skin cancer which were treated with local resection only or intraepithelial lesions or carcinoma in situ of the cervix or prostate that has been curatively treated.
- Patient must not be receiving any other investigational agents.
- Patient must not have active CNS involvement.
- Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to brentuximab vedotin or other agents used in the study.
- Patients must not have had previous radiation therapy to the mediastinum or lungs.
- Patient must not have an uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, active pulmonary diseases, or psychiatric illness/social situations that would limit compliance with study requirements (this criterion should be met on screening and on the day of but prior to first dose of brentuximab vedotin).
- Patient must not be pregnant and/or breastfeeding.
- Patient must not be known to be HIV-positive on combination antiretroviral therapies.
- Patient must not have had a previous allogeneic or syngeneic transplant. Prior autologous transplant is allowed.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Dose Level 0 (starting dose)
brentuximab vedotin 0.3mg/kg, given IV on Days 7, 28, 49 & 70
|
Andere Namen:
|
Experimental: Dose Level 1
brentuximab vedotin 0.6mg/kg, given IV on Days 7, 28, 49 & 70
|
Andere Namen:
|
Experimental: Dose Level 2
brentuximab vedotin 1.2mg/kg, given IV on Days 7, 28, 49 & 70
|
Andere Namen:
|
Experimental: Dose Level 3
brentuximab vedotin 1.8mg/kg, given IV on Days 7, 28, 49 & 70
|
Andere Namen:
|
Kein Eingriff: Control Dose Level
The first 3 patients will not receive brentuximab vedotin.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
MTD of brentuximab vedotin when administered with a GVHD prophylaxis regimen
Zeitfenster: 37 days
|
Defined as the dose level immediately below the dose level at which 2 patients of a cohort (of 2 to 6 patients) experience dose-limiting toxicity; Hematologic DLT is defined as ANC < 500/mm3 for three consecutive days beyond Day +21 that was determined by the investigator to be likely related to brentuximab vedotin. Non-hematologic DLT is defined as any grade 3 or higher non-hematologic toxicity that was determined by the investigator to be possibly, probably, or definitely related to brentuximab vedotin, with the following specific exceptions:
|
37 days
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Safety and tolerability of brentuximab vedotin when administered with a GVHD prophylaxis regimen
Zeitfenster: 100 days
|
Toxicities described and graded using CTCAE version 4.0; described by patient, type, and grade for each dose level; summarized by counts and percentage of patients in the corresponding categories
|
100 days
|
Rate of acute GVHD
Zeitfenster: 100 days
|
Proportion of all subjects who experience symptoms consistent with grade 2-4 acute GVHD; using the standard grading system adapted from the Glucksberg clinical stage and grade of acute GVHD
|
100 days
|
Rate of chronic GVHD
Zeitfenster: 2 years
|
Proportion of all subjects who experience symptoms consistent with chronic GVHD; assessment will begin after Day 100 using the NIH consensus criteria for diagnosis and staging of chronic GVHD
|
2 years
|
Progression-free survival
Zeitfenster: 2 years
|
Duration from the time of transplant to time of first progression, death, relapse after complete response, or the date the patient was last known to be in remission; estimated with Kaplan-Meier methods.
|
2 years
|
Overall survival.
Zeitfenster: 2 years
|
Duration from the time of transplant to death or last follow-up; estimated with Kaplan-Meier methods.
|
2 years
|
1-year non-relapse mortality rate
Zeitfenster: 1 year
|
Defined as the percentage of patients dying from etiologies other than disease relapse; estimated with Kaplan-Meier methods.
|
1 year
|
2-year non-relapse mortality rate
Zeitfenster: 2 years
|
Defined as the percentage of patients dying from etiologies other than disease relapse; estimated with Kaplan-Meier methods.
|
2 years
|
1-year disease relapse rate
Zeitfenster: 1 year
|
Defined as the percentage of patients who have disease relapse; estimated with Kaplan-Meier methods.
|
1 year
|
2-year disease relapse rate
Zeitfenster: 2 years
|
Defined as the percentage of patients who have disease relapse; estimated with Kaplan-Meier methods.
|
2 years
|
Mitarbeiter und Ermittler
Mitarbeiter
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Immunsystems
- Neubildungen nach histologischem Typ
- Neubildungen
- Lymphoproliferative Erkrankungen
- Lymphatische Erkrankungen
- Immunproliferative Erkrankungen
- Erkrankungen des Knochenmarks
- Hämatologische Erkrankungen
- Leukämie, lymphatisch
- Leukämie, Myeloid
- Myelodysplastische Syndrome
- Leukämie
- Leukämie, myeloisch, akut
- Vorläuferzelle lymphoblastische Leukämie-Lymphom
- Antineoplastische Mittel
- Antineoplastische Mittel, immunologische
- Brentuximab Vedotin
Andere Studien-ID-Nummern
- 201211047
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Myelodysplastische Syndrome
-
University of Colorado, DenverRekrutierungKlinefelter-Syndrom | Trisomie X | XYY-Syndrom | XXXY- und XXXXY-Syndrom | Xxyy-Syndrom | Xyyy-Syndrom | Xxxx-Syndrom | Xxxxx-Syndrom | Xxxyy-Syndrom | Xxyyy-Syndrom | Xyyyy-Syndrom | Männchen mit GeschlechtschromosomenmosaikVereinigte Staaten
-
Riphah International UniversityAbgeschlossen
-
Riphah International UniversityAbgeschlossen
-
Shaare Zedek Medical CenterUnbekanntPrämenstruelles Syndrom-PMS
-
Riphah International UniversityRekrutierungUpper-Cross-SyndromPakistan
-
Cairo UniversityNoch keine Rekrutierung
-
Cairo UniversityRekrutierung
-
Riphah International UniversityRekrutierungUpper-Cross-SyndromPakistan
-
Hrain Biotechnology Co., Ltd.Shanghai Changzheng HospitalAktiv, nicht rekrutierendPOMES-Syndrom | Rezidiviertes und refraktäres POMES-SyndromChina
-
King Saud UniversityUnbekanntImpingement-Syndrom, SchulterSaudi-Arabien
Klinische Studien zur brentuximab vedotin
-
University Hospital, CaenRekrutierung
-
TG Therapeutics, Inc.AbgeschlossenHodgkin-LymphomVereinigte Staaten
-
Fondazione Italiana Linfomi ONLUSAbgeschlossenRezidiviertes/refraktäres Hodgkin-LymphomItalien
-
Shanghai Zhongshan HospitalTakeda; BeiGeneNoch keine Rekrutierung
-
TakedaAbgeschlossenRezidiviertes oder refraktäres CD30+-Hodgkin-Lymphom oder anaplastisches großzelliges LymphomJapan
-
Seagen Inc.BeendetSystemischer Lupus erythematodesVereinigte Staaten
-
Grupo Español de Linfomas y Transplante Autólogo...RekrutierungHodgkin-Lymphom, ErwachsenerSpanien
-
Memorial Sloan Kettering Cancer CenterSeagen Inc.; Hôpitaux Universitaires Henri Mondor, FranceAbgeschlossenHodgkin-LymphomVereinigte Staaten
-
The Lymphoma Academic Research OrganisationAbgeschlossenRefraktäres peripheres T-Zell-Lymphom | Rezidiviertes peripheres T-Zell-LymphomFrankreich, Belgien
-
TakedaAbgeschlossenUnbehandeltes CD30-positives Hodgkin-LymphomJapan